Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

Core Insights - Ipsen has entered an exclusive licensing agreement for global rights outside of Greater China for SIM0613, an antibody-drug conjugate (ADC) targeting the LRRC15 protein, which is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with high unmet needs [1][2][3] Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience and operations in over 40 countries [4][5] Product Details - SIM0613 targets the LRRC15 protein, which is highly expressed in various tumor types and cancer-associated fibroblasts, allowing for selective internalization and release of a cytotoxic payload to kill cancer cells while sparing healthy cells [3][7] - The ADC is engineered for deep tumor penetration, showing robust tumor regressions in multiple in vivo preclinical models [3][7] Financial Terms - Under the licensing agreement, Simcere Zaiming is eligible to receive up to $1.06 billion in total payments, which includes upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on sales [2][7] Development Timeline - The program is expected to enter Phase I clinical development in the second half of 2026 [7]